Instrument Inactif

Communiqués Galapagos NV Euronext Bruxelles

Actions

GLPG

BE0003818359

Recherche biotechnologique et médicale

Temps réel estimé Tradegate Autres places de cotation 21:59:54 15/07/2026			Varia. 5j.	Varia. 1 janv.
25,65 ^EUR	0,00%		0,00%	-

13/07	Lakefront Biotherapeutics NV annonce la démission de Paulo Fontoura de son poste d'administrateur	CI
16/06	Lakefront Biotherapeutics NV (ENXTAM:LKFT) annonce un programme de rachat d'actions	CI

Communiqués

14/07	Acquisition of Own Shares	GL
13/07	Lakefront Announces Paulo Fontoura has Resigned from its Board following his Appointment as Global Head of R&D at Sanofi	GL
07/07	Acquisition of Own Shares	GL
30/06	Acquisition of Own Shares	GL
29/06	Lakefront Receives Transparency Notification from Madison Avenue Partners	GL
23/06	Acquisition of Own Shares	GL
17/06	Lakefront Biotherapeutics NV - Acquisition of Own Shares	AQ
16/06	Acquisition of Own Shares	GL
09/06	Lakefront Announces Initiation of €50 Million Stock Repurchase Program	GL
08/06	Lakefront Appoints Eric Hedrick, MD, as Chief Medical Officer	GL
04/06	Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline	BU
04/06	GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE	GL
26/05	Lakefront Receives Transparency Notification from Bank of America	GL
08/05	Galapagos : Anti-Bribery and Anti-Corruption Policy	PU
06/05	Galapagos Reports First Quarter 2026 Financial Results and Provides Business Update	GL
28/04	Galapagos’ Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders’ Meetings 2026	GL
31/03	Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases	GL
26/03	Galapagos : GLPG Convening Notice ENG Final2056061.1	PU
26/03	Galapagos : BE0466460429 20260326 FULL cap en2056226.1	PU
26/03	Galapagos : Statutory Auditors report Galapagos NV 2025 ENG Final2056252.1	PU
26/03	Galapagos : Board Report Renewal Authorized Capital ENG Final Website2055873.1	PU
26/03	Galapagos : Annual Report for Fiscal Year Ending 2025-12-31 (Form 20-F)	PU
26/03	Galapagos Announces Nomination of Gino Santini to its Board of Directors	GL
26/03	Galapagos Publishes 2025 Annual Report and Announces Annual and Extraordinary Shareholders’ Meetings	GL
23/03	Galapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases	GL